The treatment of immune thrombocytopenia (ITP)—focus on thrombopoietin receptor agonists
نویسندگان
چکیده
منابع مشابه
Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go on to have chronic ITP. In those children with chronic ITP who need treatment, standard therapies for acute ITP may have adverse effects that complicate their long-term use. Thus, alternative treatment options are needed for children with chronic ITP. Thrombopoietin re...
متن کاملTreatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists.
The pathophysiology, classification, epidemiology, and treatment of immune thrombocytopenia (ITP) have witnessed great progresses in the last decade and are briefly addressed here. After more than 5 years of use in clinical practice, a new class of drugs acting as thrombopoietin-receptor (TPO-R) agonists is gaining a more definite role in the treatment of primary ITP in adults. The two currentl...
متن کاملWill thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
2015 Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and increased bleeding tendency. Most children with ITP spontaneously recover. However, children with severe bleeding may require treatment. Traditional treatments such as corticosteroids or splenectomy are often associated with increased risks of infections. Currently, there is evidence that plat...
متن کاملEfficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
Background and Aim Thrombopoietin receptor agonists (TPO-RAs) have been shown to be safe and effective for adults with chronic immune thrombocytopenia (ITP). The aim of this meta-analysis is to assess the efficacy and safety of thrombopoietin receptor agonists for children with chronic ITP. Materials and Methods Clinical randomized controlled trials (RCTs) evaluating the efficacy and safety o...
متن کاملAssociation between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia.
OBJECTIVE The development of myeloid malignancies is a concern when administering thrombopoietin receptor (or the myeloproliferative leukemia virus proto-oncogene product, MPL) agonists. Progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia [AML, 9 (6.12%) AML patients among 147 MDS subjects] was reported in a clinical trial. However, only one (0.15%) case of AML among 6...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Blood
سال: 2021
ISSN: 2521-361X
DOI: 10.21037/aob-21-23